# Safety and Efficacy of BCMA-Targeted CAR-T Therapy for Relapsed/Refractory Multiple Myeloma

> **NCT04272151** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Chongqing Precision Biotech Co., Ltd** · enrollment: 40 (estimated)

## Conditions studied

- Multiple Myeloma
- Multiple Myeloma in Relapse
- Neoplasm, Plasma Cell

## Interventions

- **BIOLOGICAL:** BCMA CAR-T cells

## Key facts

- **NCT ID:** NCT04272151
- **Lead sponsor:** Chongqing Precision Biotech Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-12-01
- **Primary completion:** 2023-12-31
- **Final completion:** 2024-07-01
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2023-04-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04272151

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04272151, "Safety and Efficacy of BCMA-Targeted CAR-T Therapy for Relapsed/Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT04272151. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*